ArticleBJOG : an international journal of obstetrics and gynaecology2022
Pessary or surgery for a symptomatic pelvic organ prolapse: the PEOPLE study, a multicentre prospective cohort study.
Article in BJOG : an international journal of obstetrics and gynaecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Posterior compartment prolapse and perineal descent: systematic review of available support devices.International urogynecology journal · 2023Pooled it
- Four Year Clinical and Cost Effectiveness of Vaginal Pessary Self-Management Versus Clinic-Based Care for Pelvic Organ Prolapse (TOPSY): Long Term Follow-Up of a Randomised Controlled Superiority Trial.BJOG : an international journal of obstetrics and gynaecology · 2025Trial
- Effects of intravaginal conjugated oestrogen on pessary continuation for pelvic organ prolapse: multicentre, randomised, double blind, placebo controlled trial.BMJ (Clinical research ed.) · 2025Trial
- The influence of decisional conflict on treatment decision in pelvic organ prolapse-data from the SHADE-POP trial.Archives of gynecology and obstetrics · 2024Trial
- Trial
- Trial
- Trial
- Post-Hysterectomy Vaginal Vault Prolapse: Current Perspectives and Decision-Making Considerations for Surgical Treatment.Medicina (Kaunas, Lithuania) · 2026Review
- A Sisterhood of Women: The Process of Co-Creating Recommendations for Improved Pessary Self-Management Support.Journal of advanced nursing · 2026Article
- Fear, Shame, and Miscommunication: A Qualitative Study on Treatment Choice for Pelvic Organ Prolapse.International urogynecology journal · 2026Article
- Article
- Chapter 4.5: New Proposed Treatments for Pelvic Organ Prolapse.International urogynecology journal · 2026Review
- Article
- Discontinuation of pessary therapy within 24 months: can it be predicted?Archives of gynecology and obstetrics · 2024Observational
- The Role of Self-Management in Pessary Therapy for Pelvic Organ Prolapse-A retrospective cohort study.International urogynecology journal · 2024Article
- Quality of Life after Treatment for Pelvic Organ Prolapse in Real-World Study: Recommendations, Vaginal Pessary, and Surgery.Medicina (Kaunas, Lithuania) · 2024Observational
- Quality-of-life improvements in patients after various surgical treatments for pelvic organ prolapse.Archives of gynecology and obstetrics · 2024Review
- Are older patients with prolapse likely to continue pessary use? A retrospective observational study.International urogynecology journal · 2023Observational
- Article
- Transition to surgery after pessary among female Medicare beneficiaries with pelvic organ prolapse.American journal of obstetrics and gynecology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveTo compare the 24-month efficacy of pessary or surgery as the primary treatment for symptomatic pelvic organ prolapse (POP).
designMulticentre prospective comparative cohort study.
settingTwenty-two Dutch hospitals. POPULATION: Women referred with symptomatic POP of stage ≥2 and moderate-to-severe POP symptoms.
methodsThe primary outcome was subjective improvement at the 24-month follow-up according to the Patient Global Impression of Improvement (PGI-I) scale. Secondary outcomes included improvement in prolapse-related symptoms measured with the Pelvic Floor Distress Inventory (PFDI-20), improvement in subjective severeness of symptoms according to the Patient Global Impression of Severity (PGI-S) scale and crossover between therapies. The primary safety outcome was the occurrence of adverse events.
main outcome measurePGI-I at 24 months.
resultsWe included 539 women, with 335 women (62.2%) in the pessary arm and 204 women (37.8%) in the surgery arm. After 24 months, subjective improvement was reported by 134 women (83.8%) in the surgery group compared with 180 women (74.4%) in the pessary group (risk difference 9.4%, 95% CI 1.4-17.3%, P < 0.01). Seventy-nine women (23.6%) switched from pessary to surgery and 22 women (10.8%) in the surgery group underwent additional treatment. Both groups showed a significant reduction in bothersome POP symptoms (P ≤ 0.01) and a reduction in the perceived severity of symptoms (P ≤ 0.001) compared with the baseline.
conclusionsSignificantly more women in the surgery group reported a subjective improvement after 24 months. Both therapies, however, showed a clinically significant improvement of prolapse symptoms. TWEETABLE ABSTRACT: Pessary treatment and vaginal surgery are both efficacious in reducing the presence and severity of prolapse symptoms, although the chance of significant improvement is higher following surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.